Immunogenicity and safety of one-dose human papillomavirus vaccine compared with two or three doses in Tanzanian girls (DoRIS): an open-label, randomised, non-inferiority trial

BACKGROUND: An estimated 15% of girls aged 9–14 years worldwide have been vaccinated against human papillomavirus (HPV) with the recommended two-dose or three-dose schedules. A one-dose HPV vaccine schedule would be simpler and cheaper to deliver. We report immunogenicity and safety results of diffe...

Descripción completa

Detalles Bibliográficos
Autores principales: Watson-Jones, Deborah, Changalucha, John, Whitworth, Hilary, Pinto, Ligia, Mutani, Paul, Indangasi, Jackton, Kemp, Troy, Hashim, Ramadhan, Kamala, Beatrice, Wiggins, Rebecca, Songoro, Twaib, Connor, Nicholas, Mbwanji, Gladys, Pavon, Miquel A, Lowe, Brett, Mmbando, Devis, Kapiga, Saidi, Mayaud, Philippe, de SanJosé, Silvia, Dillner, Joakim, Hayes, Richard J, Lacey, Charles J, Baisley, Kathy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9638030/
https://www.ncbi.nlm.nih.gov/pubmed/36113531
http://dx.doi.org/10.1016/S2214-109X(22)00309-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9638030/
https://www.ncbi.nlm.nih.gov/pubmed/36113531
http://dx.doi.org/10.1016/S2214-109X(22)00309-6

Ejemplares similares